权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies

MnSOD-K68-Ac 重新编程 ER 乳腺恶性肿瘤中的谱系可塑性开关/干性

基本信息

批准号：
10327336
负责人：
David Gius
金额：
$ 36.08万
依托单位：
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-01-09 至 2025-12-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10327336
关键词：
Acetylation Adjuvant Therapy Biological Markers Biology Breast Breast Cancer Cell Cell physiology Cells Cellular Metabolic Process ChIP-seq Chemicals Cisplatin Clustered Regularly Interspaced Short Palindromic Repeats Complex Data Doxorubicin Drug Metabolic Detoxication Endocrine Equilibrium Estrogen receptor positive Event Exhibits Exposure to Fatty acid glycerol esters Fulvestrant Genes Grant Knock-out Lead Link Lysine MCF7 cell Malignant Neoplasms Mammary Neoplasms Measurement Measures Mediating Metabolic Metabolism Mitochondria Modeling Nature Oncogenic Pathway interactions Peroxidases Phenotype Physiological Post-Translational Protein Processing Property Publications Reactive Oxygen Species Recurrence Reporter Resistance Risk SOD2 gene Selective Estrogen Receptor Modulators Signal Transduction Sirtuins Stains Subgroup Superoxides Systemic Therapy T47D Tamoxifen Techniques Testing Time Tissue Microarray Tumor Promoters Woman Work Xenograft Model base breast malignancies cancer cell high risk hormone therapy in vivo knock-down mammary mimetics mitochondrial metabolism mouse model mutant neoplastic cell new therapeutic target novel patient derived xenograft model prevent public database response small hairpin RNA stem stem cell biomarkers stem-like cell stemness targeted treatment therapy resistant tissue culture transcriptome sequencing tumor tumorigenesis tumorigenic

项目摘要

SUMMARY The dysregulation of mitochondrial networks responsible for maintaining normal metabolism is an established hallmark of cancer and an early event in tumorigenesis. The disruption of cell metabolism leads to accumulation of reactive oxygen species (ROS) and triggers maladaptive signaling that disrupts metabolic balance, which can establish a tumorigenic and/or therapy resistant phenotype. In this regard, a subgroup of estrogen receptor-positive (ER+) breast malignancies, which exhibit increased ROS levels and a high risk of recurrence due to endocrine therapy, has been identified. We recently found a novel mitochondrial signaling axis centered on manganese superoxide dismutase (MnSOD), which when the acetylation (Ac) status of lysine 68 (K68-Ac) is altered, disrupts cell metabolism, leading to aberrant ROS levels (Zhu, Nature Commun., 2019). In addition, breast cancer cells expressing a MnSOD-K68-Ac mimic mutant (MnSODK68Q) exhibited increased HIF2α (known to promote stemness-like properties), increased SOX2 and Oct4 (two established stem cell biomarkers), leading to oncogenicity and pan resistance phenotype (PanR) to agents commonly used in luminal B breast malignancies-implying that disruption of cell metabolism reprograms tumors to exhibit a lineage plasticity phenotype. Based on our new data, our recent publication (Zhu et al, Nature Commun. 2019), and work by others, it is hypothesized that dysregulated MnSOD biology, due to aberrant/increased MnSOD-K68-Ac levels, disrupts normal cellular and mitochondrial metabolism. This initiates metabolic reprogramming, via increased levels of HIF2α, leading to a cell stemness-mediated tumor-permissive and/or PanR phenotype. Thus, we seek to further explore how MnSOD-K68-Ac disrupts cell metabolism and promotes a stemness-like phenotype, leading to oncogenicity and/or PanR. Finally, will GC4419 exposure, a chemical SOD detoxification mimic, reverse the oncogenic and/or PanR phenotypes?

总结